CG
STML

Cutler Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Cutler Group’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,100
Closed -$13K – 5218
2018
Q1 		$13K Buy
+2,100
New +$32.7K ﹤0.01% 2617
2017
Q4 		– Sell
-9,000
Closed -$24K – 6390
2017
Q3 		$24K Sell
9,000
-1,300
-13% -$12.2K ﹤0.01% 2981
2017
Q2 		$23K Buy
+10,300
New +$85.9K ﹤0.01% 3295
2016
Q4 		– Sell
-7,400
Closed -$12K – 7685
2016
Q3 		$12K Buy
7,400
+2,200
+42% +$17.9K ﹤0.01% 4054
2016
Q2 		$4K Buy
+5,200
New +$32.8K ﹤0.01% 5238

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cutler Group's STML Position: Q3 2019 in Review

Cutler Group sold out of Stemline Therapeutics, Inc. (STML) in Q3 2019, closing a stake of 300 shares — an estimated $4K sold.

Cutler Group first reported a position in STML in Q4 2015 and held it in 15 quarters. The position peaked at $49K in Q4 2016. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.

  • Cutler Group reported no remaining Stemline Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Cutler Group sold 300 Stemline Therapeutics, Inc. shares in Q3 2019, an estimated $4K.
  • Cutler Group first reported a position in Stemline Therapeutics, Inc. in Q4 2015 and held it in 15 quarters.
  • Cutler Group's Stemline Therapeutics, Inc. position peaked at $49K in Q4 2016.
  • 100 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2019.

Based on Cutler Group's 13F filing for Q3 2019, filed 28 Oct 2019.